| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_370ca28a580f6b11f2ed9bd04a153e55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21a837b6e77981109aa7871f1ca8c2fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eefb012b1586897bb5658f69e279741c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1632bd33771fcc6e743652a71b3aa61a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cb91f2b00063843709b125a991f1885
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ec8cb845e08d6dd7ef17f96a22166f4 |
| publicationDate |
2011-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011229487-A1 |
| titleOfInvention |
Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient |
| abstract |
Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010216977-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10730937-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010173277-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014110225-A1 |
| priorityDate |
2007-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |